Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Mar 6;10:202. doi: 10.3389/fonc.2020.00202

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2020 Urbani, Ferraresi, Capone, Macchia, Palermo, Nuzzo, Torsello, Pezzotti, Giannarelli, Pozzi, Santaquilani, Roazzi, Bastucci, Catricalà, La Malfa, Vercillo, Gualtieri, Buccione, Castiello, Cognetti, Nisticò, Belardelli, Moschella and Proietti.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Intention-to-treat analysis of relapse-free (RFS) (A,C) and overall survival (OS) (B,D) by Kaplan–Meier method. All enrolled patients were included in the analysis (n = 34). Months are calculated since time of randomization. Arm 1 patients (Pt) (n = 17) were treated with vaccination with Melan-A and NY-ESO-1 peptides (Vaccine) and interferon-α2b (IFN). Arm 2 patients (n = 17) received the same treatment of arm 1 patients with the addition of dacarbazine (DTIC) pretreatment. (A,B) Comparison between arms. (C,D) All patients (n = 34). p value by log-rank test.